An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.
Carlotta AntoniottiAlessandra BoccaccinoRobert S SeitzMirella GiordanoAurelie CatteauDaniele RossiniFilippo PietrantonioLisa SalvatoreKimberly McGregorFrancesca BergamoVeronica ConcaSimone LeonettiFederica MoranoGiorgio PapianiEmiliano TamburiniMaria BensiSabina MurgioniDouglas Teller RossAlessandro PassardiIsabelle BoquetTyler J NielsenJerome GalonMatthew Gordon VargaBrock L SchweitzerChiara CremoliniPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
DetermaIO may be useful to predict benefit of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in mCRC. The exploratory IOOPT cut-point should be validated in independent mCRC cohorts.